These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34738630)

  • 1. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
    Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gli2 mediates the development of castration‑resistant prostate cancer.
    Xia L; Bouamar H; Gu X; Zeballos C; Qin T; Wang B; Zhou Y; Wang Y; Yang J; Zhu H; Zhang W; Houghton PJ; Sun LZ
    Int J Oncol; 2020 Jul; 57(1):100-112. PubMed ID: 32319599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CACUL1 functions as a negative regulator of androgen receptor in prostate cancer cells.
    Choi H; Lee SH; Um SJ; Kim EJ
    Cancer Lett; 2016 Jul; 376(2):360-6. PubMed ID: 27085459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
    Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J
    Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
    Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
    Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression.
    Zhang M; Sun Y; Huang CP; Luo J; Zhang L; Meng J; Liang C; Chang C
    Cell Death Dis; 2021 Sep; 12(10):855. PubMed ID: 34545067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
    Liu S; Qi Y; Ge Y; Duplessis T; Rowan BG; Ip C; Cheng H; Rennie PS; Horikawa I; Lustig AJ; Yu Q; Zhang H; Dong Y
    Mol Cancer Ther; 2010 Jul; 9(7):2016-25. PubMed ID: 20571066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligophrenin-1 is associated with cell adhesion and migration in prostate cancer.
    Goto K; Oue N; Hayashi T; Shinmei S; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
    Pathobiology; 2014; 81(4):190-8. PubMed ID: 25170626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
    Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
    Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
    De Petrocellis L; Ligresti A; Schiano Moriello A; Iappelli M; Verde R; Stott CG; Cristino L; Orlando P; Di Marzo V
    Br J Pharmacol; 2013 Jan; 168(1):79-102. PubMed ID: 22594963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
    Jin R; Yamashita H; Yu X; Wang J; Franco OE; Wang Y; Hayward SW; Matusik RJ
    Oncogene; 2015 Jul; 34(28):3700-10. PubMed ID: 25220414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
    Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.